



## MEDICAL TIPS

### DIABIZ TABLETS

Issue IX, No. 33, 2022

### **The clinical efficacy and safety of Dapagliflozin in patients with diabetic nephropathy**

Huang et.al. *Diabetes Metab Syndr.* 2022; 14(1):1-6.

- Diabetic nephropathy (DN) is one of the common microvascular complications of diabetes and the present study evaluated the safety and efficacy of Dapagliflozin for the treatment of the same.
- The study comprised of control group and experimental group that received Valsartan (80 mg) and Dapagliflozin (10 mg) respectively.
- Parameters such as body mass index (BMI), hemoglobin A1C (HbA1c), serum creatinine (sCr), uric acid (UA) and urine microalbumin/urine creatinine (uMA/uCr) ratios were lower with Dapagliflozin use as compared to control group.
- Estimated glomerular filtration rate (eGFR) levels increased while serum interleukin-6 (IL-6) and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) levels reduced with Dapagliflozin and no serious events were observed with its treatment making it safe & effective for use.

**Dapagliflozin has a significant effect in the clinical treatment of patients with diabetic nephropathy demonstrated by its ability to improve diabetes, prevent nephropathy exacerbation, and reduce symptomatic reaction.**

